Literature DB >> 23958602

Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C.

Gaby Sroczynski1, Uwe Siebert.   

Abstract

A new study has reported the long-term effectiveness and cost-effectiveness of the direct-acting antivirals telaprevir and boceprevir for the treatment of chronic hepatitis C. These findings have the potential to be used to guide clinical and reimbursement decisions for treating populations with a high prevalence of HCV infection.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23958602     DOI： 10.1038/nrgastro.2013.162

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  8 in total

1.  Key principles for the improved conduct of health technology assessments for resource allocation decisions.

Authors:  Michael F Drummond; J Sanford Schwartz; Bengt Jönsson; Bryan R Luce; Peter J Neumann; Uwe Siebert; Sean D Sullivan
Journal:  Int J Technol Assess Health Care       Date:  2008       Impact factor: 2.188

2.  Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.

Authors:  G Sroczynski; E Esteban; A Conrads-Frank; R Schwarzer; N Mühlberger; D Wright; S Zeuzem; U Siebert
Journal:  J Viral Hepat       Date:  2009-07-28       Impact factor: 3.728

Review 3.  Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.

Authors:  Ziad F Gellad; Shelby D Reed; Andrew J Muir
Journal:  Antivir Ther       Date:  2012-10-05

4.  State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.

Authors:  Uwe Siebert; Oguzhan Alagoz; Ahmed M Bayoumi; Beate Jahn; Douglas K Owens; David J Cohen; Karen M Kuntz
Journal:  Med Decis Making       Date:  2012 Sep-Oct       Impact factor: 2.583

Review 5.  Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security.

Authors:  Uwe Siebert; Gaby Sroczynski
Journal:  Int J Technol Assess Health Care       Date:  2005       Impact factor: 2.188

6.  New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.

Authors:  Shan Liu; Lauren E Cipriano; Mark Holodniy; Douglas K Owens; Jeremy D Goldhaber-Fiebert
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

7.  Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Authors:  Kee Chan; Mai Ngan Lai; Erik J Groessl; Amresh D Hanchate; John B Wong; Jack A Clark; Steven M Asch; Allen L Gifford; Samuel B Ho
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-22       Impact factor: 11.382

Review 8.  Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.

Authors:  Nihar Shah; Tracey Pierce; Kris V Kowdley
Journal:  Expert Opin Investig Drugs       Date:  2013-06-04       Impact factor: 6.206
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.